Overview:

Prevalence of chronic disease such as cancer has multifarious effects on the human body. One such is oral mucositis where individuals suffer from painful lesions of the mucous membranes. This can be seen as a side-effect of the chemotherapy, and it is proportional to the growth of the chemotherapy dose. The disease can adversely affect an individual’s nutritional habits as it prevents the patient from chewing solid foods and even at times, from swallowing it. The global oral mucositis market can expect a growth of 7% during the forecast period (2017-2023), reveals Market Research Future (MRFR) in their thoroughly studied report. It further includes vital influencers and segments to provide a reliable prediction for the future market. Among chief drivers, recently patented drugs for oral mucositis are playing significant roles. Furthermore, several investments in research and development are also ensuring considerable market growth.

However, most of the medicines are costly, and some await clinical trial and license. This could deter the expected market growth during the forecast period.

Get Free Sample PDF@ https://www.marketresearchfuture.com/sample_request/1531

However, most of the medicines are costly, and some await clinical trial and license. This could deter the expected market growth during the forecast period.

Industry Trend:

Innovation Pharmaceuticals has recently signed a contract with CoreEx to develop a drug product to formulate Brilacidin in granular form, and it will be available in sachets. This is to help patients suffering from head or neck cancer receiving chemoradiation.

Researchers at Iran’s Kerman University of Medical Sciences have recently declared that the intake of Omega 3 fatty acids could treat and prevent mucositis, bringing in relief for patients who have cancer.

Izun Pharmaceuticals Corporation has revealed that they have finished the Phase 2 clinical study of IZN-6N4 which has been manufactured using botanical resources. The study is showing positive results as patients are complaining less frequently about pain.

Segmentation:

The global oral mucositis market can be segmented by cause and end-users.

Based on cause, the oral mucositis market includes oral mucositis caused by chemotherapy, oral mucositis caused by radiotherapy, and hematopoietic stem cell transplantation.

Based on end-users, the oral mucositis market includes hospitals, dental clinics, oncology hospitals, and research institutes.

Regional Analysis:

The global oral mucositis market is divided by geography into the Americas, Europe, APAC, and the Middle East and Africa. The Americas dominate the global oral mucositis market due to the widespread prevalence of cancer and widespread use of chemo- and radiotherapy to treat it. On the other hand, the oral mucositis market in APAC is rising at a steady rate and is likely to emerge as a key segment in the coming years. In the Americas, particularly North America, branded drugs are the major medicine for oral mucositis due to the presence of a highly developed medical industry. The incidence rate of anal cancer is the highest in North America among these regional segments, making it the leader in the global oral mucositis market.

Europe, APAC, and MEA markets for oral mucositis are all expected to grow considerably over the forecast period, though the incidence of anal cancer in MEA is the lowest and is likely to remain low over the forecast period.

Market Landscape:

Strategies are proving essential in taking the oral mucositis market forward. Influential companies are getting involved in a merger, acquisition, new product launch, collaborations, and other tactics to stay abreast in this market. For instance, Catalent acquired Juniper Pharmaceuticals to expand its market hold and cement its foothold in Europe. AMAG Pharmaceuticals is planning on diversification by completing divestiture in cord blood registry.

Some of the players operating for the oral mucositis are Izun Pharmaceutical Ltd (US), Shoreline Pharmaceuticals Inc. (USA), Himalaya (India), AMAG Pharmaceuticals Inc. (USA), Kinnear Pharmaceuticals (US), Celleutix Corporation (USA), Soligenix Inc. (US), Oragenics (US), and others.

Access Report @ https://www.marketresearchfuture.com/reports/oral-mucositis-market-1531

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: [email protected]